Opportunity,
I hope you are correct, but do you think this year's news and ISOBM Conference will help us any more than last year's conference? Do you think this year's news of the ELISA format test is more significant than last year's news?
Last year the ISOBM news took the share price from .46 to .86. That was great, but here we are back at .46.
IMO, we need the ISOBM - ELISA test news plus clear proof that Biocurex has made progress in this area:
Dr. Moro, CEO of BioCurex stated: ``This is an important milestone for us because it will allow us to (a) ship and demonstrate to the scientific community at large the significance of what we have developed; and (b) engage in the commercialization of Manual tests based on this format. It is worth mentioning that this format was developed in a rather short period of time because of the work done on the chemistry of RECAF over the past 2-3 years. It demonstrates our success in understanding the very unusual chemistry of RECAF well enough to suit the practical needs of a commercial test. The results are excellent and provide further evidence of the value of the RECAF blood test for cancer detection. Furthermore, our results with both formats show that bladder and kidney cancers are also detected with high sensitivity and specificity.''
BioCurex intends to expand on its plans to commercialize this test in future disclosures.
IMO, the share price won't be much better off without significant progress towards 1)validation from the scientific community, and 2) commercialization of the test.
Of course IMA could produce additional news.
mcd
